Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,255,168
  • Shares Outstanding, K 93,460
  • Annual Sales, $ 258,610 K
  • Annual Income, $ -850 K
  • 36-Month Beta -0.01
  • Price/Sales 4.79
  • Price/Cash Flow 27.77
  • Price/Book 3.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.04
  • Number of Estimates 4
  • High Estimate 0.05
  • Low Estimate 0.02
  • Prior Year 0.04
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.03 +1.69%
on 12/14/18
17.13 -22.65%
on 11/30/18
-2.75 (-17.19%)
since 11/14/18
3-Month
12.75 +3.92%
on 10/23/18
19.04 -30.41%
on 11/01/18
-0.64 (-4.61%)
since 09/14/18
52-Week
7.08 +87.15%
on 02/06/18
19.04 -30.41%
on 11/01/18
+4.19 (+46.25%)
since 12/14/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace

The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace

MEDP : 53.41 (-4.04%)
MMSI : 56.28 (-2.36%)
ANTM : 275.58 (-1.74%)
NEO : 13.25 (-1.34%)
ENSG : 42.82 (-6.20%)
5 Healthcare Bets to Stay in Investors Good Books Next Year

Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.

MEDP : 53.41 (-4.04%)
MMSI : 56.28 (-2.36%)
ANTM : 275.58 (-1.74%)
NEO : 13.25 (-1.34%)
ENSG : 42.82 (-6.20%)
NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the appointment of Lawrence M. Weiss, M.D. as Chief Scientific Officer. Dr. Weiss joined...

NEO : 13.25 (-1.34%)
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of...

MS : 39.64 (-2.36%)
MDSY : 0.73 (+4.29%)
NEO : 13.25 (-1.34%)
NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that GE Medical Systems Information Technologies, Inc. ("GE Info Tech") intends to offer...

MS : 39.64 (-2.36%)
MDSY : 0.73 (+4.29%)
NEO : 13.25 (-1.34%)
NeoGenomics Completes Acquisition of Genoptix, Inc.

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix, Inc. for $125 million...

NEO : 13.25 (-1.34%)
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach

The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.

ITGR : 84.27 (-1.33%)
VEEV : 91.39 (-0.78%)
NEO : 13.25 (-1.34%)
QGEN : 34.60 (-1.20%)
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

Partners discuss efforts to accelerate precision medicine solutions at ASH 2018

NEO : 13.25 (-1.34%)
QGEN : 34.60 (-1.20%)
Eyenovia Initiates Phase III Study for Mydriasis Candidate

Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.

NEO : 13.25 (-1.34%)
GILD : 65.57 (-2.64%)
EYEN : 3.40 (-4.76%)
ALXN : 109.43 (-2.67%)
Top 5 Companies in the Life Sciences Tools & Services Industry with the Best Relative Performance (CBM , FLDM , NEO , PACB , WAT )

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

NEO : 13.25 (-1.34%)
CBM : 41.64 (-1.86%)
FLDM : 7.78 (-4.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NEO with:

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

2nd Resistance Point 13.65
1st Resistance Point 13.45
Last Price 13.25
1st Support Level 13.04
2nd Support Level 12.83

See More

52-Week High 19.04
Fibonacci 61.8% 14.47
Last Price 13.25
Fibonacci 50% 13.06
Fibonacci 38.2% 11.65
52-Week Low 7.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar